Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1

MLA

Cervera-Carrascon, Victor, et al. “Adenovirus Armed With TNFa and IL2 Added to APD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to APD-1.” Frontiers in Immunology, vol. 12, July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....298f437b1efacbc8618ea2fb364658b5&authtype=sso&custid=ns315887.

APA

Cervera-Carrascon, V., Quixabeira, D. C. A., Santos, J. M., Havunen, R., Milenova, I., Verhoeff, J., Heiniö, C., Zafar, S., Garcia-Vallejo, J. J., van Beusechem, V. W., de Gruijl, T. D., Kalervo, A., Sorsa, S., Kanerva, A., & Hemminki, A. (2021). Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology, 12.

Chicago

Cervera-Carrascon, Victor, Dafne C.A. Quixabeira, Joao M. Santos, Riikka Havunen, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, et al. 2021. “Adenovirus Armed With TNFa and IL2 Added to APD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to APD-1.” Frontiers in Immunology 12 (July). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....298f437b1efacbc8618ea2fb364658b5&authtype=sso&custid=ns315887.